An interventional study of Percutaneous coronary intervention (PCI) and Symptom assessment during experimentally induced ischaemia in Stable Angina and Multivessel Coronary Artery Disease, sponsored by Imperial College London. Recruiting at 8 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Imperial College London · Not applicable, Interventional, and Diagnostic
ORBITA-MOON is a double-blinded, placebo-controlled experimental study that aims to understand how the different coronary artery stenoses contribute to overall clinical angina in patients with multi-vessel coronary artery disease. This study will investigate the symptoms conferred by each stenosis, induced by experimental ischaemia, for 50 patients with multi-vessel coronary artery disease.
343 studies on the registry are indexed under Angina, Stable; 56 are open to participants now.
This study's planned enrollment of 50 is below the median of 150 across 230 interventional studies indexed under Angina, Stable.
Browse Angina, Stable studies →Imperial College London is the lead sponsor of 843 studies on the registry; 180 are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 6 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
The criteria were revised on the registry on Oct 28, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Anatomical evidence of significant multi-vessel coronary stenosis defined by either:
Physiological evidence of ischaemia with a positive test corresponding to the coronary arteries to be stented, on at least one of the following:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients who: 1. Are symptomatic with angina 2. Have anatomically severe multi-vessel coronary artery disease 3. Have physiological evidence of myocardial ischaemia
Procedure: Percutaneous coronary intervention (PCI) · Diagnostic Test: Symptom assessment during experimentally induced ischaemia
Coronary artery stenting for stable angina
Transient experimental balloon occlusion across coronary stenosis to determine the symptoms conferred by ischaemia at this stenosis.
Placebo-controlled similarity score during induced ischaemia at the coronary stenosis
The patient scores the similarity of the angina experienced during the experimental balloon inflation procedure against the angina experienced before the procedure between 0-10 (Higher Score = Most similar)
Time frame: Intra-procedural
Placebo-controlled intensity score during induced ischaemia at the coronary stenosis
The patient scores the severity of the angina experienced during the experimental balloon inflation procedure between 0-10 (Higher Score = More severe)
Time frame: Intra-procedural
Angina symptom type during induced ischaemia at the coronary stenosis
The patient will list all symptoms experienced during the experimental balloon inflation procedure.
Time frame: Intra-procedural
Change in angina symptom score
Fractional Change in Angina Frequency (0-1) (Lower Score = Better Outcome)
Time frame: 57 days
Angina severity as assessed by Canadian Cardiovascular Society Class
Canadian Cardiovascular Society Class (0-IV) (Lower Score = Better Outcome)
Time frame: 57 days
Angina severity as assessed by MRC dyspnoea scale
MRC dyspnoea score (1-5) (Lower Score = Better Outcome)
Time frame: 57 days
Physical limitation, angina stability, quality of life, angina frequency, freedom from angina as assessed with the Seattle Angina Questionnaire
Seattle Angina Questionnaire (0-100), (Higher Score = Better Outcome)
Time frame: 57 days
Quality of Life assessed with the EQ-5D-5L questionnaire
EQ-5D-5L Questionnaire (-0.59 to 1), (Higher Score = Better Outcome)
Time frame: 57 days
Psychological impact of angina as assessed by the PHQ-9 questionnaire
PHQ-9 Questionnaire (0-27), (Lower Score = Better Outcome)
Time frame: 57 days
Psychological impact of angina as assessed by the Beck Depression Inventory
Beck Depression Inventory (0-63), (Lower Score = Better Outcome)
Time frame: 57 days
Psychological impact of angina as assessed by the Coping Strategies Questionnaire
Coping Strategies Questionnaire (13-52), (Higher Score = Better Outcome)
Time frame: 57 days
Psychological impact of angina as assessed by the Pain Catastrophizing Scale
Pain Catastrophizing Scale (0-52), (Lower Score = Better Outcome)
Time frame: 57 days
Psychological impact of angina as assessed by the Profile of mood states questionnaire
Profile of mood states Questionnaire (0-44), (Lower Score = Better Outcome)
Time frame: 57 days
Psychological impact of angina as assessed by the SCL-90 Questionnaire
SCL-90 Questionnaire (0-360), (Lower Score = Better Outcome)
Time frame: 57 days
Need for anti-anginal medication introduction and uptitration
Has the patient required anti-anginal introduction and/or uptitration. (Score 0-1), (0 = no, 1 = yes)
Time frame: 57 days
Angina type as assessed by the Rose Chest Pain Questionnaire
Rose Chest Pain Questionnaire (Score positive or negative), (Positive = pain suggestive of coronary heart disease, negative = pain not suggestive of coronary artery disease)
Time frame: 57 days
Angina type as assessed by the McGill Pain Questionnaire
McGill Pain Questionnaire (Score 0-78), (Lower Score = Better Outcome)
Time frame: 57 days
Plan to share: No
No publications or documents are linked to this record.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.